A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease

NCT04371653 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped lack of funds

Conditions

Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus

Interventions

DRUG: PRIM-DJ2727
DRUG: Placebo

Sponsor

The University of Texas Health Science Center, Houston